Aegis Capital and Chardan Capital Markets are bookrunners for the deal
By Devika Patel
Knoxville, Tenn., Feb. 17 – Signal Genetics, Inc. said it priced its $9 million public offering of stock with a $1.35 million greenshoe. The offering was announced Jan. 15.
The company will sell 3,214,285 common shares at $2.80 per share. The price per share reflects a 28.39% discount to the Feb. 13 closing share price of $3.91.
Aegis Capital Corp. and Chardan Capital Markets, LLC are the bookrunning managers.
Settlement is expected Feb. 20.
Proceeds will be used for clinical development, commercialization, working capital and general corporate purposes.
The molecular genetic diagnostic company is based in Carlsbad, Calif.
| Issuer: | Signal Genetics, Inc.
|
| Issue: | Common stock
|
| Amount: | $9 million
|
| Greenshoe: | $1.35 million
|
| Shares: | 3,214,285
|
| Price: | $2.80
|
| Warrants: | No
|
| Bookrunners: | Aegis Capital Corp. and Chardan Capital Markets, LLC
|
| Announcement date: | Jan. 15
|
| Pricing date: | Feb. 16
|
| Settlement date: | Feb. 20
|
| Stock symbol: | Nasdaq: SGNL
|
| Stock price: | $3.91 at close Feb. 13
|
| Market capitalization: | $10.67 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
